Damaged Brains May Repair Themselves If Given Enough Energy

For more than a century, Alzheimer’s disease has carried a quiet finality. Once cognitive decline begins, the medical consensus has been to slow the damage, not reverse it. A new study from Cleveland researchers challenges that assumption entirely, showing that mice with advanced Alzheimer’s-like disease can recover full cognitive function when their brain’s energy supply is restored.

The work centers on NAD+, a molecule essential for cellular energy. NAD+ levels naturally decline with age, but the drop is far more severe in Alzheimer’s. In mice engineered to develop the disease, brain energy fell 30% by six months of age and plummeted to a 45% deficit by one year. The team from University Hospitals and Case Western Reserve University used a compound called P7C3-A20 to restore that balance. Unlike over-the-counter supplements that can push NAD+ to dangerous, cancer-promoting levels, this molecule acts like a tuner, helping stressed cells maintain their own equilibrium.

The results went beyond halting progression. Mice with significant brain pathology and memory loss returned to normal. Under the microscope, the blood-brain barrier had repaired itself. Neuroinflammation that had left neural tissue looking frayed and scarred was significantly reduced. Mice that previously struggled to recognize new objects or navigate familiar paths suddenly performed as well as healthy counterparts.

Two Models, Same Recovery

The researchers tested the treatment on two different mouse models: one driven by amyloid plaques, the other by tau tangles, the two primary hallmarks of human Alzheimer’s. Despite their different genetic causes, both showed consistent recovery. Blood levels of p-tau217, a biomarker currently used to diagnose Alzheimer’s in humans, dropped significantly following treatment. The findings suggest that early cognitive impairment might stem from a loss of brain resilience rather than the permanent death of neurons.

“Restoring the brain’s energy balance achieved pathological and functional recovery in both lines of mice with advanced Alzheimer’s. Seeing this effect in two very different animal models, each driven by different genetic causes, strengthens the idea that restoring the brain’s NAD+ balance might help patients recover from Alzheimer’s,” Andrew A. Pieper explains.

The team also found reason for optimism in human brain samples. The severity of Alzheimer’s in people directly correlates with the level of NAD+ disruption in the cerebral cortex. More intriguing: they identified a group of resilient individuals who have the physical signs of Alzheimer’s but never developed dementia. These people appear to have naturally preserved their brain’s energy homeostasis.

From Managing Loss to Enabling Repair

Pieper, who directs the Brain Health Medicines Center at the Harrington Discovery Institute, was clear about the boundary between animal models and human disease. Alzheimer’s remains uniquely human, and whether this recovery can be achieved in patients will require carefully designed clinical trials. The findings build on earlier work from the same group showing that restoring NAD+ balance could drive recovery after severe traumatic brain injury, suggesting that energy failure may be a common bottleneck in neurological damage.

If the approach translates to humans, it could reframe what those trials aim for. Instead of asking only how to slow decline, the question becomes whether recovery is possible. The implications extend beyond Alzheimer’s alone, potentially representing a broader strategy for treating chronic, age-related neurodegenerative diseases.

Cell Reports Medicine: 10.1016/j.xcrm.2025.102535